Greenwich LifeSciences Completes Enrollment in FLAMINGO-01
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is excited to share that it has successfully completed enrollment in the open label non-HLA-A*02 arm of its pivotal Phase III clinical trial, FLAMINGO-01. This trial focuses on GLSI-100, a promising immunotherapy aimed at preventing recurrences of breast cancer. Notably, this achievement marks a significant milestone in the clinical journey of the drug.
The FLAMINGO-01 Trial Overview
FLAMINGO-01 consists of several components designed to evaluate GLSI-100. Among them, the double-blinded arms will include around 500 HLA-A*02 patients, who will be randomized to receive GLSI-100 or a placebo. Moreover, up to 250 patients who do not possess the HLA-A*02 allele will be treated within the open label arm. These patients represent roughly 55% of the overall FLAMINGO-01 cohort.
A Major Milestone in Enrollment
Upon completing the enrollment of the 250 patients in the open label non-HLA-A*02 segment, Greenwich LifeSciences achieved a significant milestone made possible by a high screening and enrollment rate. The company is actively analyzing the latest data from this group, especially focusing on recurrence rates, which could be announced or published at any time.
Future Steps in Trial Enrollment
The company previously halted enrollment in this arm and is currently discussing with regulatory agencies about resuming randomized enrollment for new non-HLA-A*02 patients alongside a control arm. They continue conducting screenings to ensure rapid enrollment once regulatory approval is granted.
Immunotherapy Potential of GLSI-100
Earlier this year, the company reported encouraging early observations. The preliminary analysis indicates that the immune response seen at the baseline before treatment and during the primary immunization series suggests a similar trend among parents with the HLA-A*02 alleles. With breast cancer recurrence rates dropping by as much as 80% in previous trials, there’s optimism about continuing this trend moving forward.
CEO's Insights on Progress and Research
CEO Snehal Patel shared insights about the importance of analyzing data from the treated patients: "Our analysis allows for a detailed comparison of recurrence rates. With a significantly larger group of patients receiving GLSI-100 now, we can draw more reliable conclusions. We eagerly anticipate updating our stakeholders and the broader community on our findings through publications and conferences, similar to how we shared insights from the Phase IIb trials conducted from 2020 to 2022."
Expanding Patient Accessibility
Mr. Patel highlighted that the application of GLSI-100 to non-HLA-A*02 patients is an innovative aspect of their research. The firm believes that the patent claims associated with this innovation will avoid licensing fees or royalties, potentially doubling the patient population eligible for treatment in the U.S. and Europe to about 88,000 new patients annually, with a market opportunity that could reach between $8 to $10 billion.
Broadening Enrollment Criteria
The common non-HLA-A*02 types enrolled include HLA-A*03, HLA-A*24, HLA-A*01, and others. The ongoing enrollment of HLA-A*02 patients in the randomized arms remains unaffected, allowing the company to effectively increase the trial size without falling behind on interim analyses.
Conclusion and Ongoing Commitment
Greenwich LifeSciences continues to examine various aspects of immunotherapy in breast cancer treatments through the FLAMINGO-01 trial. As they progress, they remain dedicated to sharing vital updates with stakeholders and potential investors about their results and any regulatory developments.
Frequently Asked Questions
What is the main goal of the FLAMINGO-01 trial?
The primary goal is to evaluate the efficacy of GLSI-100 as an immunotherapy to prevent recurrences in breast cancer patients.
How many patients have been enrolled in the trial so far?
Enrollment has reached 250 patients in the open label arm and is expected to grow in various segments.
What is GLSI-100?
GLSI-100 is a novel immunotherapy aimed at preventing breast cancer recurrences, specifically in patients who have undergone surgery.
What promising results have so far been reported from the trial?
The trial has reported decreased recurrence rates of up to 80%, with ongoing assessments suggesting positive trends.
How can I learn more about participating in the trial?
For information regarding participation, interested individuals can contact the company through their provided email address.
